Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

AbbVie To Present New Data From Antibody-Drug Conjugate (ADC) Platform At ESMO Congress 2024, Highlighting Mirvetuximab Soravtansine For Ovarian Cancer, Telisotuzumab Vedotin And Adizutecan For Non-Small Cell Lung And Gastroesophageal Cancers

Author: Benzinga Newsdesk | September 09, 2024 09:08am

Full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating mirvetuximab soravtansine (ELAHERE®), for high folate receptor-alpha (FRα) expressing platinum-sensitive ovarian cancer (PSOC) (mini-oral presentation).
Exploratory patient reported outcomes (PROs) from the Phase 2 LUMINOSITY trial, evaluating telisotuzumab vedotin (Teliso-V), a potential first-in-class c-Met directed antibody-drug conjugate (ADC), in advanced non-small cell lung cancer (NSCLC).
New safety and efficacy data in pre-treated patients with advanced NSCLC (mini-oral presentation) and gastroesophageal cancer (GEA), from a Phase 1 study of telisotuzumab adizutecan (ABBV-400), a next-generation, potential best-in-class c-Met directed ADC.

Posted In: ABBV